At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 148 enrolled
Drug / intervention
Glatiramer Acetate 20 mg/0.5 mL +1 moredrug
Likely dose
Glatiramer Acetate 20 mg/0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study Evaluating Patient Injection Satisfaction With Two Formulations of Glatiramer Acetate (GA) Using Autoject 2 as the Subcutaneous Injection Delivery Method.
In Brief
A Phase 3 clinical trial evaluating Glatiramer Acetate 20 mg/0.5 mL and Glatiramer acetate 20 mg/0.5 mL for Multiple Sclerosis. Completed, enrolled 148 participants.
Detailed Summary
This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedJul 2010
Primary CompletionNov 2010
Study CompletionDec 2010
TodayJul 2026
First PostedJul 22, 2010
Enrollment StartJul 1, 2010
Primary CompletionNov 1, 2010
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.9 years ago
Interventions
Glatiramer Acetate 20 mg/0.5 mLdrug
20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
Glatiramer acetate 20 mg/0.5 mLdrug
20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.